Management of pressure ulcers

American Journal of Health-System Pharmacy

Volumn 61, Issue 18, 2004, Pages 1895-1907

  Cannon, Bradley C ^a   Cannon, Joan P ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b HINES VA HOSPITAL   (United States)

Author keywords

Antiinfective agents; Decubitus ulcer; Dressings; Economics; Epidemiology; Growth factors; Nutrition; Wound healing

Indexed keywords

ALGINIC ACID; ANTIBIOTIC AGENT; BECAPLERMIN; CALCIUM ALGINATE; CHLOROPHYLL; COLLAGENASE; FIBROBLAST GROWTH FACTOR; GENTAMICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; METRONIDAZOLE; NERVE GROWTH FACTOR; PAPAIN; PLATELET DERIVED GROWTH FACTOR; POVIDONE IODINE; SEALANT; SODIUM CHLORIDE; SULFADIAZINE SILVER; ZINC;

ANTIBIOTIC THERAPY; ARTIFICIAL SKIN; BACTERIAL COLONIZATION; COST EFFECTIVENESS ANALYSIS; CREAM; DEBRIDEMENT; DECUBITUS; DRUG EFFICACY; DRUG POTENCY; ERYTHEMA; FEVER; FOAM; GEL; HUMAN; HYDROCOLLOID; HYDROGEL; MALNUTRITION; MINERAL DEFICIENCY; NUTRITIONAL REQUIREMENT; NUTRITIONAL STATUS; OSTEOMYELITIS; PRIORITY JOURNAL; PROTEIN DIET; RASH; REVIEW; RISK FACTOR; RISK REDUCTION; SEPSIS; SKIN ULCER; STAGING; ULCER HEALING; URINARY TRACT INFECTION; VITAMIN DEFICIENCY; WOUND CARE; WOUND DRESSING; WOUND HEALING;

EID: 8344221102     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.18.1895     Document Type: Review

References (74)

1. Dealey C. Review of advances in pressure ulcer management since 1992. Br J Nurs. 2002; 11:486-90.
2. Xakellis GC, Frantz RA. The costeffectiveness of interventions for preventing pressure ulcers. J Am Board Fam Pract. 1996; 9(2):79-85.
3. Kerstein MD. Unexpected economics of ulcer care protocols. South Med J. 2004; 97:135-6.
4. Gallagher S. Outcomes in clinical practice: pressure ulcer prevalence and incidence studies. Ostomy Wound Manag. 1997; 43:28-32,34-5,38.
5. Wysocki AB. Skin anatomy, physiology, and pathophysiology. Nurs Clin North Am. 1999; 34:777-97.
6. Burkitt HG, Young B, Heath JW. Wheater's functional histology: a text and colour atlas. Edinburgh, Scotland: Churchill Livingstone; 1993.
7. Wysocki AB. A review of the skin and its appendages. Adv Wound Care. 1995; 8(2, part 1):53-4,56-62,64.
8. Goldsmith LA. Physiology, biochemistry, and molecular biology of the skin. New York: Oxford Univ. Press; 1991.
9. Mast BA, Schultz GS. Interactions of cytokines, growth factors, and proteases in acute and chronic wounds. Wound Repair Regen. 1996; 4:411-20.
10. Goldman R. Growth factors and chronic wound healing: past, present, and future. Adv Skin Wound Care. 2004; 17(1):24-35.
11. Mauch C, Kreig T, Bauer RA. Role of the extracellular matrix in the degradation of connective tissue. Arch Dermatol Res. 1994; 287:107-14.
12. Hunt TK. Basic principles of wound healing. J Trauma. 1990; 30:122s-8s.
13. Meehan M. National pressure ulcer prevalence survey. Adv Wound Care. 1994; 7(3):27-30,34,36-8.
14. Thomas DR. Age-related changes in wound healing. Drugs Aging. 2001; 18: 607-20.
15. Patterson JA, Bennett RG. Prevention and treatment of pressure sores. J Am Geriatr Soc. 1995; 43:919-27.
16. Schouchoff B. Pressure ulcer development in the operating room. Crit Care Nurs Q. 2002; 25(1):76-82.
17. Alessi CA, Ouslander JG, Maldague S et al. Incidence and costs of acute medical conditions in long-stay incontinent nursing home residents. J Am Med Dir Assoc. 2003; 4:S5-18.
18. Allman RM. Pressure ulcers among the elderly. N Engl J Med. 1989; 320:850-3.
19. Higley HR, Ksander GA, Gerhardt CO et al. Extravasation of macromolecules and possible trapping of transforming growth factor-beta in venous ulceration. Br J Dermatol. 1995; 132:79-85.
20. National Pressure Ulcer Advisory Panel. Staging report. www.npuap.org/ positn6.html (accessed 2004 Feb 17).
21. Breslow RA, Hallfrisch J, Guy DG et al. The importance of dietary protein in healing pressure ulcers. J Am Geriatr Soc. 1993; 41:357-62.
22. Chernoff RS, Milton KY, Lipschitz DA. The effect of a high protein formulation (Replete) on decubitus ulcer healing in long term tube fed institutionalized patients. J Am Diet Assoc. 1990; 90:A-130.
23. Pinchcofsky-Devin GD, Kaminski MV. Correlation of pressure sores and nutritional status. J Am Geriatr Soc. 1996; 34: 435-40.
24. Bergstrom N, Braden B. A prospective study of pressure sore risk among institutionalized elderly. J Am Geriatr Soc. 1992; 40:747-58.
25. Berlowitz DR, Wilking SV. Risk factors for pressure sores. A comparison of cross-sectional and cohort-derived data. J Am Geriatr Soc. 1989; 37:1043-50.
26. Henderson CT, Trumbore LS, Mobarhan S et al. Prolonged tube feeding in long-term care: nutritional status and clinical outcomes. J Am Coll Nutr. 1992; 11:309-25.
27. Ter Riet G, Kessels AH, Knipschild PG. Randomized clinical trial of ascorbic acid in the treatment of pressure ulcers. J Clin Epidemiol. 1995; 48:1453-60.
28. Sandstead HH, Henriksen LK, Greger JL et al. Zinc nutriture in the elderly in relation to taste acuity, immune response, and wound healing. Am J Clin Nut. 1982; 36:1046-59.
29. Calianno C. How to choose the right treatment and dressing for the wound. Nurs Manag. 2003; 34(1):6-14.
30. Constantine BE, Bolton LL. A wound model for ischemic ulcers in the guinea pig. Arch Dermatol Res. 1986; 278:429-31.
31. Thomas DR. Prevention and treatment of pressure ulcers: what works? What doesn't. Cleve Clin J Med. 2001; 68:704-22.
32. Wound care information network: types of wound debridement. www. medicaledu.com/debridhp.htm (accessed 2004 Feb 19).
33. Wound procedures: debridement. www.woundsl.com/care/ procedure20.cfm/13 (accessed 2004 Feb 19).
34. Wound care strategies. Consumer's corner. Definitions, products, and manufacturers. www.woundcarestrategies.com/ top.htm (accessed 2004 Feb 17).
35. Walker D. Back to basics: choosing the correct wound dressing. Am J Nurs. 1996; 96(9):35-9.
36. Rothe M, Falanga V. Growth-factors. Arch Dermatol. 1989; 125:1390-8.
37. Landi F, Aloe L, Russo A et al. Topical treatment of pressure ulcers with nerve growth factor: a randomized clinical trial. Ann Intern Med. 2003; 139:635-41.
38. Dinarello CA, Cannon JG, Mier JW et al. Multiple biological activities of human recombinant interleukin 1. J Clin Invest. 1986; 77:1734-9.
39. Dinarello CA. Interleukin-1. Rev Infect Dis. 1984; 6(1):51-95.
40. Kaushansky K, Lin N, Adamson JW. Interleukin 1 stimulates fibroblasts to synthesize granulocyte-macrophage and granulocyte colony-stimulating factors. J Clin Invest. 1988; 81:92-7.
41. Robson MC, Abdullah A, Burns BF et al. Safety and effect of topical recombinant human interleukin-1β in the management of pressure sores. Wound Rep Regen. 1994; 2:177-81.
42. Gospodarowicz D, Ferrara N, Schweigerer et al. Structural characterization and biological functions of fibroblast growth factor. Endocr Rev. 1987; 8(2):95-114.
43. Rifkin DB, Moscatelli D. Recent developments in the cell biology of basic fibroblast growth factor. J Cell Biol. 1989; 109:1-6.
44. Hebda PA, Klingbeil CK, Abraham JA et al. Basic fibroblast growth factor stimulation of epidermal wound healing in pigs. J Invest Dermatol. 1990; 95:626-31.
45. Fiddes JC, Hebda PA, Hayward P. Pre-clinical wound-healing studies with recombinant human basic fibroblast growth factor. Ann N Y Acad Sci. 1991; 638:316-28.
46. Robson M, Phillips LG, Lawrence WT. The safety and effect of topically applied recombinant basic fibroblast growth factor on the healing of chronic pressure sores. Ann Surg. 1992; 216:401-6.
47. Robson MC, Hill DP, Smith PD. Sequential cytokine therapy for pressure ulcers: clinical and mechanistic response. Ann Surg. 2000; 231:600-11.
48. Thomas DR. The promise of topical growth factors in healing pressure ulcers. Ann Intern Med. 2003; 139:694-5. Editorial.
49. Matsuda H, Koyama H, Sato H et al. Role of nerve growth factor in cutaneous wound healing: accelerating effects in normal and healing-impaired diabetic mice. J Exp Med. 1998; 187:297-306.
50. Li AK, Koroly AJ, Schattenkerk ME. Nerve growth factor: acceleration of the rate of wound healing in mice. Proc Natl Acad Sci USA. 1980; 77:4379-81.
51. Robson MC, Phillips LG. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet. 1992; 339:23-5.
52. Pierce GF, Mustoe TA, Altrock BW et al. Role of platelet-derived growth factor in wound healing. J Cell Biol. 1991; 45:319-26.
53. Deuel TF, Senior RM, Huang JS et al. Chemotaxis of monocytes and neutrophils to platelet-derived growth factor. J Clin Invest. 1982; 69:1046-9.
54. Tzeng DY, Deuel TF, Huang JS et al. Platelet-derived growth factor promotes human peripheral monocyte activation. Blood. 1985; 66:179-83.
55. Mustoe TA, Cutler NR, Allman RM et al. A Phase II study to evaluate recombinant platelet-derived growth factor-BB in the treatment of stage 3 and 4 pressure ulcers. Arch Surg. 1994; 129:213-9.
56. Rees RS, Robson MC, Smiell JM et al. Becaplermin gel in the treatment of pressure ulcers: a Phase II randomized, double-blind, placebo-controlled study. Wound Rep Regen. 1999; 7:141-7.
57. Brem H, Balledux J, Bloom T et al. Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent: a new paradigm in wound healing. Arch Surg. 2000; 135:627-34.
58. Bello Y, Phillips TJ. Recent advances in wound healing. JAMA. 2000; 283:716-8.
59. Apligraf product information. East Hanover, NJ: Novartis Pharmaceutical Corporation; 2002 Feb.
60. Dermagraft product information. http:// wound.smith-nephew.com/US/ Product.asp?NodeId=2550 (accessed 2004 Feb 19).
61. Thomson PD, Smith DJ. What is infection? Am J Surg. 1994; 167(1A):7S-11S.
62. Hutchinson JJ, Lawrence JC. Wound infection under occlusive dressings. J Hosp Infect. 1991; 17:83-94.
63. Daltrey DC, Rhodes B, Chattwood JG. Investigation into the microbial flora of healing and non-healing decubitis ulcers. J Clin Pathol. 1981; 34:701-5.
64. Sapico FL, Ginunas VJ, Thornhill-Jones M et al. Quantitative microbiology of pressure sores in different stages of healing. Diagn Microbiol Infect Dis. 1986; 5:31-8.
65. Rudensky B, Lipschits M, Isaacsohn M et al. Infected pressure sores: comparison of methods for bacterial identification. South Med J. 1992; 85:901-3.
66. Sugarman B, Hawes S, Musher DM et al. Osteomyelitis beneath pressure sores. Arch Intern Med. 1983; 143:683-8.
67. Thornhill-Joynes M, Gonzales D, Stewart CA et al. Osteomyelitis associated with pressure ulcers. Arch Phys Med Rehabil. 1986; 67:314-8.
68. Darouiche RO, Landon GC, Klima M et al. Osteomyelitis associated with pressure sores. Arch Intern Med. 1994; 154:753-8.
69. Galpin JE, Chow AW, Bayer AS et al. Sepsis associated with decubitus ulcers. Am J Med. 1976; 61:346-50.
70. Bryan CS, Dew CE, Reynolds KL. Bacteremia associated with decubitus ulcers. Arch Intern Med. 1983; 143:2093-5.
71. Bendy RH, Nuccio PA, Wolfe E et al. Relationship of quantitative wound bacterial counts to healing of decubiti: effect of topical gentamicin. Antimicrob Agents Chemother. 1964; 4:147-55.
72. Kucan JO, Robson MC, Heggers JP et al. Comparison of silver sulfadiazine, povidone-iodine and physiologic saline in the treatment of chronic pressure ulcers. J Am Geriatr Soc. 1981; 29:232-5.
73. Gomolin IH, Brandt JL. Topical metronidazole therapy for pressure sores of geriatric patients. J Am Geriatr Soc. 1983; 31:710-2.
74. Witkowski JA, Parish LC. Topical metronidazole gel. The bacteriology of decubitus ulcers. Int J Dermatol. 1991; 30: 660-1.